Balanced news tone
News Sentiment
AZN sentiment intelligence
AstraZeneca PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
35 relevant articles
News tone and price action are not far from neutral.
88/100 classification confidence.
directly relevant articles
high-authority source matches
-1.7% over one week, -4.9% over four weeks, trend inactive, and near fair-value range.
Why AstraZeneca (LSE:AZN) Is Reframing Blue-Chip Stocks
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
88/100 classification
One-week reaction
-1.7%
Price digesting
Trend fit
Trend inactive
-4.9% over four weeks
Fair value
12.5%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
7
Neutral
23
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Kalkine Media
Direct company coverage
Why AstraZeneca (LSE:AZN) Is Reframing Blue-Chip Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 05:48
- Source
- Kalkine Media
Kalkine Media
Direct company coverage
Why AstraZeneca (LSE:AZN) Is Back In London’s Blue-Chip Debate
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 05:48
- Source
- Kalkine Media
Market source
Direct company coverage
AstraZeneca (LSE:AZN) Stock Fair Value Edges Lower After Pipeline And Pricing Debate
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 20 Jun 2026 02:07
- Source
- Market source
simplywall.st
Direct company coverage
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 16:33
- Source
- simplywall.st
Market source
Direct company coverage
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Undervalued After Recent Pullback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 13:09
- Source
- Market source
Market source
Direct company coverage
Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 18 Jun 2026 22:15
- Source
- Market source
Stock Titan
Direct company coverage
AstraZeneca (AZN) officer receives Ordinary Share award under incentive plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 20:05
- Source
- Stock Titan
TradingView
Direct company coverage
FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 16:53
- Source
- TradingView
TradingView
Direct company coverage
AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 14:07
- Source
- TradingView
simplywall.st
Direct company coverage
AstraZeneca Stock And Two Cash Flow Sleepers The Market Misprices
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 16 Jun 2026 13:16
- Source
- simplywall.st
DirectorsTalk Interviews
Direct company coverage
AstraZeneca PLC (AZN) Stock Analysis: Robust Revenue Growth and a 20.73% Upside Potential
- Tone
- Positive 82/100
- Event
- Earnings
- Published
- 09 Jun 2026 08:39
- Source
- DirectorsTalk Interviews
Market source
Direct company coverage
Is It Too Late To Reassess AstraZeneca (LSE:AZN) After Its Strong Multi‑Year Run?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 30.8% One-Year Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- simplywall.st
Financial Times
Direct company coverage
AstraZeneca chief warns group could withhold new drugs in Europe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Jun 2026 07:00
- Source
- Financial Times
simplywall.st
Direct company coverage
AstraZeneca (LSE:AZN) Valuation Check After Recent Share Price Weakness And Pipeline Growth Expectations
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Jun 2026 07:00
- Source
- simplywall.st
Stock Titan
Direct company coverage
AstraZeneca (AZN) admits 14,120 new employee scheme shares to LSE
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- Stock Titan
TradingKey
Direct company coverage
AstraZeneca PLC Stock (AZN) Closed Down by 3.17% on Jun 1: Facts Behind the Movement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 07:00
- Source
- TradingKey
Market source
Direct company coverage
A Fresh Look At AstraZeneca (LSE:AZN) Valuation After Recent Share Price Weakness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Is AstraZeneca PLC (AZN) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
UK's FTSE 100 Closes Lower; NatWest, AstraZeneca Shares Down
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 01 May 2026 07:00
- Source
- Market source
Reuters
Direct company coverage
UK's FTSE 100 slips as losses in energy stocks and AstraZeneca weigh
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 01 May 2026 07:00
- Source
- Reuters
Market source
Direct company coverage
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 15 Apr 2026 07:00
- Source
- Market source
Investing.com
Direct company coverage
AstraZeneca admits 45,750 new shares to London Stock Exchange main market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Mar 2026 07:00
- Source
- Investing.com
The Guardian
Direct company coverage
AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 10 Feb 2026 08:00
- Source
- The Guardian
Investing.com UK
Direct company coverage
FTSE 100 today: Index falls as BP halts buyback; AstraZeneca, Barclays in focus
- Tone
- Negative 34/100
- Event
- Capital return
- Published
- 10 Feb 2026 08:00
- Source
- Investing.com UK
fDi Intelligence
Direct company coverage
AstraZeneca bets big on China
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Feb 2026 08:00
- Source
- fDi Intelligence
AstraZeneca
Direct company coverage
AstraZeneca begins trading on the New York Stock Exchange
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Feb 2026 08:00
- Source
- AstraZeneca
Business Live
Direct company coverage
AstraZeneca begins trading on New York Stock Exchange
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Feb 2026 08:00
- Source
- Business Live
AstraZeneca
Direct company coverage
AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 20 Jan 2026 08:00
- Source
- AstraZeneca
Pharmaceutical Executive
Direct company coverage
AstraZeneca Stock Becomes UK’s Biggest Stock
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Nov 2025 08:00
- Source
- Pharmaceutical Executive